New Dutch Foundation to Address High Medicines Pricing Announces Plan to File Complaint with...
The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will...
Wrapping up 2025: A tumultuous year for global public health law & policy
The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...
Decision on intellectual property waiver over Covid technology on hold till 2021; what are...
Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer.
The...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
Medicines Law & Policy’s director, Ellen ’t Hoen, receives high Netherlands honour for her...
Ellen 't Hoen has been appointed Officer of the Order of Oranje-Nassau, a royal award which recognises those who merit particular appreciation from society...
Medicines Law & Policy responds to US Health and Human Services Department request for...
On 12 December 2023 the US Health and Human Services Department (HHS) posted a notice and request for comments on “the implications of access...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
Wrapping up 2020 with some noteworthy medicines, law and policy events
Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...
The Role of Activism in Shaping Law and Policies that Support Access to Medicines
This article is also available as a PDF here.
Almost 26 years ago, here in Amsterdam, on November 25-26, 1999, Health Action International, Médecins Sans...
Price, profit and the Covid-19 health technology pool: The example of remdesivir
We cannot yet know the precise trajectory of the Covid-19 pandemic, nor which therapies or vaccines will eventually prove most effective in its treatment...